HLB TherapeuticsLtd (A115450) Stock Overview
A biotech company, develops pharmaceutical products in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A115450 from our risk checks.
A115450 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
HLB Therapeutics Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,195.00 |
| 52 Week High | ₩11,800.00 |
| 52 Week Low | ₩2,720.00 |
| Beta | -0.97 |
| 1 Month Change | 14.93% |
| 3 Month Change | -1.08% |
| 1 Year Change | -72.69% |
| 3 Year Change | -43.08% |
| 5 Year Change | -71.14% |
| Change since IPO | -71.59% |
Recent News & Updates
Improved Revenues Required Before HLB Therapeutics Co.,Ltd. (KOSDAQ:115450) Shares Find Their Feet
Dec 02
Revenues Not Telling The Story For HLB Therapeutics Co.,Ltd. (KOSDAQ:115450) After Shares Rise 26%
Jun 17HLB TherapeuticsLtd (KOSDAQ:115450) Has Debt But No Earnings; Should You Worry?
May 29Recent updates
Improved Revenues Required Before HLB Therapeutics Co.,Ltd. (KOSDAQ:115450) Shares Find Their Feet
Dec 02Revenues Not Telling The Story For HLB Therapeutics Co.,Ltd. (KOSDAQ:115450) After Shares Rise 26%
Jun 17HLB TherapeuticsLtd (KOSDAQ:115450) Has Debt But No Earnings; Should You Worry?
May 29Some HLB Therapeutics Co.,Ltd. (KOSDAQ:115450) Shareholders Look For Exit As Shares Take 25% Pounding
Mar 19HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) 36% Share Price Surge Not Quite Adding Up
Jan 03HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) Shares Climb 36% But Its Business Is Yet to Catch Up
Nov 18What HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) 36% Share Price Gain Is Not Telling You
Nov 18Is HLB TherapeuticsLtd (KOSDAQ:115450) A Risky Investment?
Sep 25What HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) 27% Share Price Gain Is Not Telling You
Jul 22HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) Popularity With Investors Under Threat As Stock Sinks 26%
Jun 03HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) 38% Share Price Surge Not Quite Adding Up
Apr 11There's Reason For Concern Over HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) Massive 50% Price Jump
Feb 26Does G-treeBNT (KOSDAQ:115450) Have A Healthy Balance Sheet?
Mar 19Did Business Growth Power G-treeBNT's (KOSDAQ:115450) Share Price Gain of 134%?
Dec 21
Shareholder Returns
| A115450 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -2.4% | -2.9% | 5.7% |
| 1Y | -72.7% | 49.0% | 87.0% |
Return vs Industry: A115450 underperformed the KR Biotechs industry which returned 49% over the past year.
Return vs Market: A115450 underperformed the KR Market which returned 87% over the past year.
Price Volatility
| A115450 volatility | |
|---|---|
| A115450 Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 12.1% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A115450 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A115450's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 49 | Ki Hong Ahn | hlbtherapeutics.co.kr |
HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrical and electronic components, such as motors, pumps, and transformers.
HLB Therapeutics Co.,Ltd. Fundamentals Summary
| A115450 fundamental statistics | |
|---|---|
| Market cap | ₩264.89b |
| Earnings (TTM) | -₩7.99b |
| Revenue (TTM) | ₩63.25b |
Is A115450 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A115450 income statement (TTM) | |
|---|---|
| Revenue | ₩63.25b |
| Cost of Revenue | ₩56.01b |
| Gross Profit | ₩7.23b |
| Other Expenses | ₩15.22b |
| Earnings | -₩7.99b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -95.18 |
| Gross Margin | 11.43% |
| Net Profit Margin | -12.64% |
| Debt/Equity Ratio | 11.7% |
How did A115450 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/20 09:17 |
| End of Day Share Price | 2026/01/20 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HLB Therapeutics Co.,Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jae Kim | DAOL Investment & Securities Co., Ltd. |